JP2009542696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542696A5 JP2009542696A5 JP2009518393A JP2009518393A JP2009542696A5 JP 2009542696 A5 JP2009542696 A5 JP 2009542696A5 JP 2009518393 A JP2009518393 A JP 2009518393A JP 2009518393 A JP2009518393 A JP 2009518393A JP 2009542696 A5 JP2009542696 A5 JP 2009542696A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- group
- substituted
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 **N1CCOCC1 Chemical compound **N1CCOCC1 0.000 description 4
- GKOAQPMFDRAARM-ULKWEWGCSA-N CC(C)C1(C)SC=C(CN(C)C(N[C@@H](C(C)COC)C(O)=O)=O)N1 Chemical compound CC(C)C1(C)SC=C(CN(C)C(N[C@@H](C(C)COC)C(O)=O)=O)N1 GKOAQPMFDRAARM-ULKWEWGCSA-N 0.000 description 1
- AYNKEDQCQUBXKC-PXTZSQHASA-N CC(C)[C@@H](C(N(C)[C@H](CC[C@H](Cc1ccccc1)NC(OCc1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O Chemical compound CC(C)[C@@H](C(N(C)[C@H](CC[C@H](Cc1ccccc1)NC(OCc1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O AYNKEDQCQUBXKC-PXTZSQHASA-N 0.000 description 1
- FYFOKJMLOCALAN-QSCLJHCWSA-N CC(C)[C@@H](C(N[C@H](CC[C@H](Cc1ccccc1)NC(/[O]=C/c1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O Chemical compound CC(C)[C@@H](C(N[C@H](CC[C@H](Cc1ccccc1)NC(/[O]=C/c1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O FYFOKJMLOCALAN-QSCLJHCWSA-N 0.000 description 1
- MERJVZJITHOBLN-ZIHXJKBXSA-N CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(NCCC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(NCCC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)=O)=O)c[s]1 MERJVZJITHOBLN-ZIHXJKBXSA-N 0.000 description 1
- WJGZIEIFZQIJPA-KFJBMODSSA-N CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(OC)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(OC)=O)=O)c[s]1 WJGZIEIFZQIJPA-KFJBMODSSA-N 0.000 description 1
- LQRJNXNJJBAJRE-PUCLRWMGSA-N CC(C)c1nc(CN(C)C(N[C@@H](C/C(/O)=[O]/C)C(N[C@H](CC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)Cc2ccccc2)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](C/C(/O)=[O]/C)C(N[C@H](CC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)Cc2ccccc2)=O)=O)c[s]1 LQRJNXNJJBAJRE-PUCLRWMGSA-N 0.000 description 1
- UGINBIFFWPEJLE-GLGOKHISSA-N CC(C)c1nc(CN(C)C(N[C@H](C(C)OC(C)(C)C)C(O)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@H](C(C)OC(C)(C)C)C(O)=O)=O)c[s]1 UGINBIFFWPEJLE-GLGOKHISSA-N 0.000 description 1
- FYCWLJLGIAUCCL-BKLSDQPFSA-N CC([C@@H](C(O)=O)N)OC Chemical compound CC([C@@H](C(O)=O)N)OC FYCWLJLGIAUCCL-BKLSDQPFSA-N 0.000 description 1
- ZGSFKAVIRXLMRI-AKGZTFGVSA-N CC([C@@H](C(OC)=O)N)OC Chemical compound CC([C@@H](C(OC)=O)N)OC ZGSFKAVIRXLMRI-AKGZTFGVSA-N 0.000 description 1
- IFKONDWPXROQGA-UHFFFAOYSA-N OC([n]1cncc1)=S Chemical compound OC([n]1cncc1)=S IFKONDWPXROQGA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81931506P | 2006-07-07 | 2006-07-07 | |
| US60/819,315 | 2006-07-07 | ||
| US83237106P | 2006-07-21 | 2006-07-21 | |
| US60/832,371 | 2006-07-21 | ||
| US90322807P | 2007-02-23 | 2007-02-23 | |
| US60/903,228 | 2007-02-23 | ||
| PCT/US2007/015604 WO2008010921A2 (en) | 2006-07-07 | 2007-07-06 | Modulators of pharmacokinetic properties of therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011239688A Division JP2012051933A (ja) | 2006-07-07 | 2011-10-31 | 治療薬の薬物動態の調整 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009542696A JP2009542696A (ja) | 2009-12-03 |
| JP2009542696A5 true JP2009542696A5 (https=) | 2011-02-17 |
| JP4881433B2 JP4881433B2 (ja) | 2012-02-22 |
Family
ID=38729072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518393A Active JP4881433B2 (ja) | 2006-07-07 | 2007-07-06 | 治療薬の薬物動態の調整 |
| JP2011239688A Withdrawn JP2012051933A (ja) | 2006-07-07 | 2011-10-31 | 治療薬の薬物動態の調整 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011239688A Withdrawn JP2012051933A (ja) | 2006-07-07 | 2011-10-31 | 治療薬の薬物動態の調整 |
Country Status (33)
| Country | Link |
|---|---|
| US (11) | US8067449B2 (https=) |
| EP (5) | EP4566670A3 (https=) |
| JP (2) | JP4881433B2 (https=) |
| KR (3) | KR101477822B1 (https=) |
| CN (2) | CN101490023B (https=) |
| AP (1) | AP2985A (https=) |
| AR (1) | AR061838A1 (https=) |
| AU (1) | AU2007275860C1 (https=) |
| BR (1) | BRPI0714055B8 (https=) |
| CA (1) | CA2653374A1 (https=) |
| CY (2) | CY1116688T1 (https=) |
| DK (1) | DK2049506T4 (https=) |
| EA (2) | EA020489B1 (https=) |
| ES (4) | ES2611308T3 (https=) |
| FI (2) | FI2049506T4 (https=) |
| FR (1) | FR15C0078I2 (https=) |
| HR (2) | HRP20090077B1 (https=) |
| HU (1) | HUE025565T4 (https=) |
| IL (2) | IL195488A (https=) |
| LT (1) | LTC2049506I2 (https=) |
| LU (1) | LU92864I2 (https=) |
| ME (1) | ME02258B (https=) |
| MX (1) | MX2009000234A (https=) |
| NL (1) | NL300780I1 (https=) |
| NO (4) | NO343776B1 (https=) |
| NZ (1) | NZ573060A (https=) |
| PL (2) | PL2049506T5 (https=) |
| PT (2) | PT2487165T (https=) |
| RS (1) | RS54237B2 (https=) |
| SG (1) | SG183007A1 (https=) |
| SI (1) | SI2049506T2 (https=) |
| TW (2) | TWI496778B (https=) |
| WO (1) | WO2008010921A2 (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| PL2049506T5 (pl) * | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| EP2081917A2 (en) * | 2006-08-31 | 2009-07-29 | Abbott Laboratories | Cytochrome p450 oxidase inhibitors and uses thereof |
| SI2487162T1 (sl) | 2007-02-23 | 2016-12-30 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtskih sredstev |
| MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| AU2013204817B2 (en) * | 2007-02-23 | 2015-05-07 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| AU2015204378B2 (en) * | 2007-02-23 | 2017-03-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US20100331331A1 (en) * | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
| AR067184A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| ES2438275T3 (es) * | 2007-07-06 | 2014-01-16 | Gilead Sciences, Inc. | Moduladores de propiedades farmacocinéticas de agentes terapéuticos |
| WO2009067225A2 (en) * | 2007-11-20 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Boceprevir derivatives for the treatment of hcv infections |
| US8759379B2 (en) * | 2008-01-04 | 2014-06-24 | Gilead Sciences, Inc. | Inhibitors of cytochrome P450 |
| ES2572631T3 (es) | 2008-01-25 | 2016-06-01 | Chimerix, Inc. | Métodos de tratamiento de infecciones virales |
| MX2010011963A (es) * | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| EP2393485B1 (en) * | 2009-02-06 | 2015-07-29 | Gilead Sciences, Inc. | Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir |
| UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| SG184324A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| UY33310A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Sintesis estereoselectiva de activos que contienen fosforo |
| EP2418196A1 (en) * | 2010-07-29 | 2012-02-15 | IMTM GmbH | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors |
| MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| WO2012045007A1 (en) | 2010-10-01 | 2012-04-05 | Gilead Sciences, Inc. | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| WO2012088153A1 (en) * | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
| AU2012250890B2 (en) | 2011-05-02 | 2015-05-28 | Gilead Sciences, Inc. | Amorphous solid salts |
| EP2729130B1 (en) | 2011-07-07 | 2017-09-06 | Janssen Sciences Ireland UC | Darunavir combination formulations |
| ES2608871T5 (es) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| CA2860995A1 (en) | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
| US9346796B2 (en) | 2012-02-03 | 2016-05-24 | Gilead Sciences, Inc. | Methods and intermediates for preparing pharmaceutical agents |
| HK1204980A1 (en) | 2012-03-01 | 2015-12-11 | Gilead Sciences, Inc. | Spray dried formulations |
| WO2014000178A1 (en) * | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| CN104540813A (zh) * | 2012-06-27 | 2015-04-22 | 默沙东公司 | 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法 |
| CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| WO2014105777A1 (en) * | 2012-12-26 | 2014-07-03 | Assia Chemical Industries Ltd. | Cobicostat dichlohydrate salt |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| WO2014194519A1 (en) | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug |
| CN104370777A (zh) * | 2013-08-13 | 2015-02-25 | 上海迪赛诺化学制药有限公司 | 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用 |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| WO2015070366A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| WO2015070367A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| US20170035911A1 (en) | 2013-11-29 | 2017-02-09 | Mylan Laboratories Ltd. | Amorphous Cobicistat Solid Dispersion |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| CN105198829B (zh) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | 一种可比司他中间体的制备方法及其中间体和用途 |
| TW201728582A (zh) | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | 結晶型 |
| WO2017160922A1 (en) | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| CN105884760B (zh) * | 2016-06-13 | 2019-01-04 | 厦门市蔚嘉化学科技有限公司 | 一种可比司他中间体的制备方法 |
| CN107674039A (zh) * | 2016-08-01 | 2018-02-09 | 上海朴颐化学科技有限公司 | 一种可比西他中间体的制备方法 |
| CA3032813A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| WO2018064071A1 (en) | 2016-09-27 | 2018-04-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| US11185548B2 (en) | 2016-12-23 | 2021-11-30 | Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| EP3889200B1 (en) | 2018-11-26 | 2023-09-20 | Mitsubishi Gas Chemical Company, Inc. | Aqueous epoxy resin composition and cured product of same |
| CN111329858B (zh) * | 2018-12-18 | 2022-09-20 | 深圳先进技术研究院 | 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用 |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| PL4244396T3 (pl) | 2020-11-11 | 2025-12-22 | Gilead Sciences, Inc. | Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 |
| CR20240223A (es) | 2021-12-03 | 2024-07-08 | Gilead Sciences Inc | Compuestos terapéuticos para la infección por el virus del vih |
| US12404262B2 (en) | 2021-12-03 | 2025-09-02 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121219281A (zh) | 2023-05-31 | 2025-12-26 | 吉利德科学公司 | 用于治疗hiv的化合物的固体形式 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354866A (en) * | 1966-04-25 | 1967-11-28 | Frank D Karkoska | Coating apparatus including means to rotate and translate a rod-substrate |
| US3882114A (en) * | 1967-10-26 | 1975-05-06 | Oreal | N-(morpholinomethyl carbamyl) cysteamine and glycine |
| GB1339764A (en) * | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
| US3957774A (en) * | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
| US5142056A (en) | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| HU186777B (en) | 1981-07-09 | 1985-09-30 | Magyar Tudomanyos Akademia | Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them |
| DE3478684D1 (en) * | 1983-11-02 | 1989-07-20 | Magyar Tudomanyos Akademia | Crown ether derivatives |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5362912A (en) | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
| US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| EP0428849A3 (en) | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
| US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| IE20010533A1 (en) * | 1990-11-20 | 2003-03-05 | Abbott Lab | Intermediates for preparing retroviral protease inhibiting compounds |
| JPH06127981A (ja) | 1992-03-03 | 1994-05-10 | Fuainiteii Kk | 複合複層ガラス及びそれを使用した窓 |
| US5556418A (en) * | 1993-07-06 | 1996-09-17 | Pappas; Panagiotis T. | Method and apparatus for pulsed magnetic induction |
| US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| CA2170020C (en) | 1992-12-29 | 2005-08-02 | Dale J. Kempf | Retroviral protease inhibiting compounds |
| US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5763464A (en) | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| WO1999033792A2 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
| FR2773994B1 (fr) | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
| FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
| TR200103488T2 (tr) * | 1999-06-04 | 2002-04-22 | Abbott Laboratories | Geliştirilmiş farmasötik formülasyonlar. |
| PL204924B1 (pl) | 1999-10-06 | 2010-02-26 | Tibotec Pharm Ltd | Heksahydrofuro [2,3-b] furanylo-3-N-{3(1,3-benzodioksolilo-5-sulfonylo) (izobutylo) amino] -1-benzylo-2-hydroksypropylo} karbaminian oraz jego zastosowanie |
| US6252336B1 (en) | 1999-11-08 | 2001-06-26 | Cts Corporation | Combined piezoelectric silent alarm/battery charger |
| WO2001082919A2 (en) | 2000-05-04 | 2001-11-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of and compounds for inhibiting calpains |
| US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7193065B2 (en) | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
| US7285566B2 (en) | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
| EP1467970B1 (en) | 2002-01-17 | 2007-08-22 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| US7205413B2 (en) * | 2002-05-03 | 2007-04-17 | Transform Pharmaceuticals, Inc. | Solvates and polymorphs of ritonavir and methods of making and using the same |
| SK2662004A3 (sk) | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
| JP2004184681A (ja) * | 2002-12-03 | 2004-07-02 | Konica Minolta Holdings Inc | 熱現像感光材料 |
| DK1583542T3 (da) | 2003-01-14 | 2008-09-22 | Gilead Sciences Inc | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| US7737608B2 (en) | 2003-07-30 | 2010-06-15 | The Boeing Company | Enhanced amplitude piezoelectric motor apparatus and method |
| JP2005091988A (ja) * | 2003-09-19 | 2005-04-07 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料及び画像形成方法 |
| JP2007509950A (ja) * | 2003-10-27 | 2007-04-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ処置の組合せ剤 |
| BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| JP2006003701A (ja) * | 2004-06-18 | 2006-01-05 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料および画像形成方法 |
| CA2571726C (en) * | 2004-07-06 | 2013-05-21 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
| US7786153B2 (en) * | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| PL2049506T5 (pl) * | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| EP2081917A2 (en) | 2006-08-31 | 2009-07-29 | Abbott Laboratories | Cytochrome p450 oxidase inhibitors and uses thereof |
| MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| US20100331331A1 (en) | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
| AR067184A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| ES2438275T3 (es) | 2007-07-06 | 2014-01-16 | Gilead Sciences, Inc. | Moduladores de propiedades farmacocinéticas de agentes terapéuticos |
| EP2416157B1 (en) | 2007-12-27 | 2014-07-30 | Baxter International Inc. | Method and compositions for specifically detecting physiologically acceptable polymer molecules |
| MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| EP2393485B1 (en) | 2009-02-06 | 2015-07-29 | Gilead Sciences, Inc. | Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir |
-
2007
- 2007-07-06 PL PL07836007.0T patent/PL2049506T5/pl unknown
- 2007-07-06 WO PCT/US2007/015604 patent/WO2008010921A2/en not_active Ceased
- 2007-07-06 HR HRP20090077AA patent/HRP20090077B1/hr not_active IP Right Cessation
- 2007-07-06 PT PT121675946T patent/PT2487165T/pt unknown
- 2007-07-06 CN CN2007800256073A patent/CN101490023B/zh active Active
- 2007-07-06 CA CA002653374A patent/CA2653374A1/en not_active Abandoned
- 2007-07-06 ME MEP-2015-590A patent/ME02258B/me unknown
- 2007-07-06 ES ES12167594.6T patent/ES2611308T3/es active Active
- 2007-07-06 AP AP2008004720A patent/AP2985A/xx active
- 2007-07-06 EA EA200900155A patent/EA020489B1/ru active Protection Beyond IP Right Term
- 2007-07-06 US US12/306,198 patent/US8067449B2/en active Active
- 2007-07-06 US US11/825,605 patent/US7939553B2/en active Active
- 2007-07-06 HU HUE07836007A patent/HUE025565T4/en unknown
- 2007-07-06 EP EP25158282.1A patent/EP4566670A3/en active Pending
- 2007-07-06 KR KR1020097002544A patent/KR101477822B1/ko active Active
- 2007-07-06 MX MX2009000234A patent/MX2009000234A/es active IP Right Grant
- 2007-07-06 SI SI200731667T patent/SI2049506T2/sl unknown
- 2007-07-06 SG SG2012050464A patent/SG183007A1/en unknown
- 2007-07-06 CN CN201310141408.6A patent/CN103275033B/zh active Active
- 2007-07-06 EP EP20167933.9A patent/EP3696171B1/en active Active
- 2007-07-06 TW TW102126891A patent/TWI496778B/zh active
- 2007-07-06 NZ NZ573060A patent/NZ573060A/en unknown
- 2007-07-06 HR HRP20150744TT patent/HRP20150744T4/hr unknown
- 2007-07-06 PL PL20167933.9T patent/PL3696171T3/pl unknown
- 2007-07-06 PT PT78360070T patent/PT2049506E/pt unknown
- 2007-07-06 AU AU2007275860A patent/AU2007275860C1/en active Active
- 2007-07-06 DK DK07836007.0T patent/DK2049506T4/da active
- 2007-07-06 EP EP07836007.0A patent/EP2049506B2/en active Active
- 2007-07-06 ES ES20167933T patent/ES3026665T3/es active Active
- 2007-07-06 KR KR1020157008020A patent/KR101636221B1/ko active Active
- 2007-07-06 EP EP12167594.6A patent/EP2487165B1/en active Active
- 2007-07-06 ES ES16180602T patent/ES2796275T3/es active Active
- 2007-07-06 RS RS20150590A patent/RS54237B2/sr unknown
- 2007-07-06 BR BRPI0714055A patent/BRPI0714055B8/pt active IP Right Grant
- 2007-07-06 TW TW096124727A patent/TWI411613B/zh active
- 2007-07-06 AR ARP070103029A patent/AR061838A1/es active IP Right Grant
- 2007-07-06 KR KR1020137033735A patent/KR20140004808A/ko not_active Ceased
- 2007-07-06 EP EP16180602.1A patent/EP3112355B1/en active Active
- 2007-07-06 EA EA201270738A patent/EA025845B1/ru active Protection Beyond IP Right Term
- 2007-07-06 JP JP2009518393A patent/JP4881433B2/ja active Active
- 2007-07-06 ES ES07836007T patent/ES2546378T5/es active Active
-
2008
- 2008-11-25 IL IL195488A patent/IL195488A/en active IP Right Grant
-
2009
- 2009-02-06 NO NO20090593A patent/NO343776B1/no active Protection Beyond IP Right Term
-
2011
- 2011-05-09 US US13/103,970 patent/US8383655B2/en active Active
- 2011-10-31 JP JP2011239688A patent/JP2012051933A/ja not_active Withdrawn
-
2013
- 2013-01-10 US US13/738,764 patent/US20130123311A1/en not_active Abandoned
- 2013-12-20 US US14/137,555 patent/US20140105859A1/en not_active Abandoned
-
2014
- 2014-04-29 IL IL232320A patent/IL232320A0/en unknown
- 2014-05-02 US US14/268,891 patent/US20150011775A1/en not_active Abandoned
-
2015
- 2015-01-20 US US14/601,132 patent/US9139541B2/en active Active
- 2015-08-17 US US14/828,406 patent/US20160067360A1/en not_active Abandoned
- 2015-09-14 CY CY20151100800T patent/CY1116688T1/el unknown
- 2015-11-06 FI FIEP07836007.0T patent/FI2049506T4/fi active
- 2015-11-06 FI FIC20150052C patent/FIC20150052I1/fi unknown
- 2015-11-06 LU LU92864C patent/LU92864I2/xx unknown
- 2015-11-11 LT LTPA2015040C patent/LTC2049506I2/lt unknown
- 2015-11-26 CY CY2015046C patent/CY2015046I1/el unknown
- 2015-12-02 FR FR15C0078C patent/FR15C0078I2/fr active Active
- 2015-12-08 NL NL300780C patent/NL300780I1/nl unknown
-
2016
- 2016-03-17 US US15/073,367 patent/US20160303088A1/en not_active Abandoned
- 2016-11-01 US US15/340,466 patent/US20170143680A1/en not_active Abandoned
-
2017
- 2017-12-05 US US15/831,703 patent/US20180221348A1/en not_active Abandoned
-
2019
- 2019-04-23 NO NO20190528A patent/NO345343B1/no unknown
- 2019-07-04 NO NO2019027C patent/NO2019027I1/no unknown
- 2019-07-19 NO NO2019031C patent/NO2019031I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4881433B2 (ja) | 治療薬の薬物動態の調整 | |
| JP6192776B2 (ja) | 治療薬の薬物動態特性の調節 | |
| JP2009542696A5 (https=) | ||
| JP5629585B2 (ja) | シトクロムｐ４５０のインヒビター | |
| JP5393665B2 (ja) | 治療剤の薬物動態特性の調整剤 | |
| JP2010519314A5 (https=) | ||
| NO20200578A1 (no) | Modulatorer av farmakokinetikkegenskaper til terapeutika | |
| HK1143144B (en) | Modulators of pharmacokinetic properties of therapeutics | |
| NO20230434A1 (no) | Modulatorer av farmakokinetikkegenskaper til terapeutika |